| Abstract [eng] |
High Density Lipoprotein Cholesterol Efflux Capacity in High Cardiovascular Risk Patients Introduction. Cholesterol efflux capacity is the process by which high-density lipoproteins (HDLs) can take cholesterol from macrophages and transfer them to the liver where cholesterol is removed from body thru bile. HDL cholesterol removal facilitates reverse cholesterol transport. By standardizing this method, it can be used as a clinical trial for cardiovascular disease and monitoring the effectiveness of treatment. The aim of the study was to evaluate the capacity of high density lipoprotein cholesterol to be administered to healthy and cardiovascular risk patients. Methods. The study included 95 patients aged from 27 to 60 years. Sample of people were divided into healthy and sickly dyslipidaemia, also by gender as women and men. Sample had a total cholesterol and other lipid metabolism rates. The fluorescence intensity of HDL cholesterol efflux capacity was measured by a spectrophotometer and the cholesterol efflux capacity was calculated according to the formula for all patients. Results. Cholesterol efflux capacity in healthy patients (46,25%), in patients with dyslipidaemia (43,95%), (p=0,32). Weak negative association between cholesterol efflux capacity and HDL – Ch (r= – 0,33; p=0,03) was found in sick patients group. Women's cholesterol capacity (43,42%), men (46,84%), (p=0,14). There is no relationship between the cholesterol efflux capacity and the lipid metabolism rates. Cholesterol efflux capacity between healthy women (46,7%) and men (45,81%), (p=0,81). In the healthy male group, a weakly negative association was found between the cholesterol efflux capacity and Apo E (r= – 0,46; p=0,02). There is statistically significant difference (p<0,01) in che cholesterol efflux capacity between (40,14%) women with dyslipidemia and (47,92%) men with dyslipidemia, statistically significant scores were detected (p<0,01). Cholesterol efllux capacity younger patients (46,11%), older (44,39%), (p=0,46). The HDL cholesterol efflux capacity of younger patients had a negative correlation with HDL – Ch (r= – 0,41; p<0,01), Apo B (r= – 0,39; p=0,01) , Apo B/Apo AI (r= – 0,44; p<0,01). Conclusions. HDL cholesterol efflux capacity in dyslipidemia patients had weak negative correlation with HDL – Ch (r= – 0,33; p=0,03). Cholesterol efflux capacity in the healty male group had weak negative correlation with Apo E (r= – 0,46; p=0,02). Cholesterol efflux capacity had statistically significant differences only between woman with dyslipidemia (40,14%) and man with dyslipidemia (47,92%) (p<0,01), it was higher in man with dyslipidemia than in woman with dyslipidemia. Cholesterol efflux capacity in healty patients group was (46,25%) and (43,95%) in dyslipidemia patients. No statistically significant differences found between healthy and dyslipidemia patients (p = 0.32). |
